Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
1992-5-21
|
| pubmed:abstractText |
The primary pulmonary hypertension is a severe disease with bad prognosis. It can be subdivided into three subtypes with various vasoreactive properties of the arterial lung blood vessels what is important to know concerning the medicamentous therapy. Long term effects of vasodilators are still in dispute, although, recently some drugs with vasodilating properties seem to be promising in the treatment of primary pulmonary hypertension. The heart-lung-transplantation could be an alternative in therapy.
|
| pubmed:language |
ger
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
0303-657X
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
177
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
117-34
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading | |
| pubmed:year |
1991
|
| pubmed:articleTitle |
[Primary pulmonary hypertension. An overview with special reference to risk-benefit analysis of therapy].
|
| pubmed:affiliation |
Forschungsinstitut für Lungenkrankheiten und Tuberkulose Berlin-Buch.
|
| pubmed:publicationType |
Journal Article,
English Abstract,
Review
|